Kamran Mushtaq1, Zubair Khan2, Muhammad Aziz2, Zakaria Abdullah Alyousif3, Nauman Siddiqui4, Muhammad Ali Khan5, Ali Nawras6. 1. Department of Medicine, Hamad General Hospital and Weill-Cornell Medical College, Doha, Qatar. 2. Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, USA. 3. Department of Respiratory Care, University of Toledo Medical center, Toledo, OH, USA. 4. Department of Hematology & Oncology, Tufts Medical Center, Boston, MA, USA. 5. Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA. 6. Department of Gastroenterology & Hepatology, University of Toledo Medical Center, Toledo, OH, USA.
Abstract
BACKGROUND: Immunosuppressive therapy is being increasingly used in the management of inflammatory bowel disease (IBD) which comprises of ulcerative colitis (UC) and Crohn's disease (CD). Patients on immunosuppressive therapy are at increased risk of developing opportunistic fungal infections. We conducted this analysis to describe the epidemiology of opportunistic fungal infections in this cohort. METHODS: We analyzed the National Inpatient Sample (NIS) database for all subjects with discharge diagnosis of IBD (UC and Crohn's disease) & Fungal infections (Histoplasmosis, Pneumocystosis, Cryptococcosis, Aspergillosis, Blastomycosis, candidiasis, Coccidioidomycosis) as primary or secondary diagnosis via ICD 9 codes during the period from 2002-2014. RESULTS: In UC, the incidence of all fungal infections was more in age above 50 (except for pneumoconiosis) male gender (except Candidiasis) and in Caucasians. In CD, the incidence was more in age above 50 (except Pneumocystosis, Blastomycosis & Coccidioidomycosis), female gender (except Histoplasmosis, Pneumocystosis & Cryptococcosis) and in Caucasians. Histoplasmosis and Blastomycosis were more prevalent in Midwest, Cryptococcosis and Candidiasis in South, Coccidioidomycosis in west in both UC and CD. Age above 50, south region, HIV, Congestive heart failure, underlying malignancies, diabetes mellitus with complications, chronic pulmonary disease, anemia, rheumatoid arthritis, collagen vascular disease, pulmonary circulation disorders, weight loss were significant predictors of fungal infections in IBD. The yearly trend showed a consistent small rise in incidence, and the mortality dropped till 2006 to peak again in 2008 with a subsequent decline. CONCLUSIONS: Our study is the first one to describe the basic demographics features and characteristics of opportunistic fungal infections in hospitalized patients with IBD. The yearly incidence of fungal infections did not show a significant rise. The mortality increased between 2006-2008 and a significant difference remains between IBD patients with and without fungal infections. One explanation of rise in mortality but a consistent incidence could be due to the use of biologics that did not increase but compromised the ability of IBD patients to fight opportunistic fungal infections. 2020 Translational Gastroenterology and Hepatology. All rights reserved.
BACKGROUND: Immunosuppressive therapy is being increasingly used in the management of inflammatory bowel disease (IBD) which comprises of ulcerative colitis (UC) and Crohn's disease (CD). Patients on immunosuppressive therapy are at increased risk of developing opportunistic fungal infections. We conducted this analysis to describe the epidemiology of opportunistic fungal infections in this cohort. METHODS: We analyzed the National Inpatient Sample (NIS) database for all subjects with discharge diagnosis of IBD (UC and Crohn's disease) & Fungal infections (Histoplasmosis, Pneumocystosis, Cryptococcosis, Aspergillosis, Blastomycosis, candidiasis, Coccidioidomycosis) as primary or secondary diagnosis via ICD 9 codes during the period from 2002-2014. RESULTS: In UC, the incidence of all fungal infections was more in age above 50 (except for pneumoconiosis) male gender (except Candidiasis) and in Caucasians. In CD, the incidence was more in age above 50 (except Pneumocystosis, Blastomycosis & Coccidioidomycosis), female gender (except Histoplasmosis, Pneumocystosis & Cryptococcosis) and in Caucasians. Histoplasmosis and Blastomycosis were more prevalent in Midwest, Cryptococcosis and Candidiasis in South, Coccidioidomycosis in west in both UC and CD. Age above 50, south region, HIV, Congestive heart failure, underlying malignancies, diabetes mellitus with complications, chronic pulmonary disease, anemia, rheumatoid arthritis, collagen vascular disease, pulmonary circulation disorders, weight loss were significant predictors of fungal infections in IBD. The yearly trend showed a consistent small rise in incidence, and the mortality dropped till 2006 to peak again in 2008 with a subsequent decline. CONCLUSIONS: Our study is the first one to describe the basic demographics features and characteristics of opportunistic fungal infections in hospitalized patients with IBD. The yearly incidence of fungal infections did not show a significant rise. The mortality increased between 2006-2008 and a significant difference remains between IBD patients with and without fungal infections. One explanation of rise in mortality but a consistent incidence could be due to the use of biologics that did not increase but compromised the ability of IBD patients to fight opportunistic fungal infections. 2020 Translational Gastroenterology and Hepatology. All rights reserved.
Entities:
Keywords:
Fungal infections; inflammatory bowel disease (IBD); national inpatient sample
Authors: Axel U Dignass; Christoph Gasche; Dominik Bettenworth; Gunnar Birgegård; Silvio Danese; Javier P Gisbert; Fernando Gomollon; Tariq Iqbal; Konstantinos Katsanos; Ioannis Koutroubakis; Fernando Magro; Guillaume Savoye; Jürgen Stein; Stephan Vavricka Journal: J Crohns Colitis Date: 2014-12-03 Impact factor: 9.071
Authors: A N Ananthakrishnan; R Guzman-Perez; V Gainer; T Cai; S Churchill; I Kohane; R M Plenge; S Murphy Journal: Aliment Pharmacol Ther Date: 2012-02-23 Impact factor: 8.171
Authors: Megan E McAuliffe; Stephan Lanes; Timothy Leach; Asit Parikh; Gerald Faich; Jane Porter; Crystal Holick; Daina Esposito; Yueqin Zhao; Irving Fox Journal: Curr Med Res Opin Date: 2015-08-20 Impact factor: 2.580
Authors: Mathias L Richard; Bruno Lamas; Giuseppina Liguori; Thomas W Hoffmann; Harry Sokol Journal: Inflamm Bowel Dis Date: 2015-03 Impact factor: 5.325
Authors: Maheen Z Abidi; Nayantara Coelho-Prabhu; James Hargreaves; Tim Weiland; Irminne Van Dyken; Aaron Tande; Pritish K Tosh; Randall C Walker; Nathan W Cummins Journal: Case Rep Med Date: 2014-04-27